Working… Menu

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00553800
Recruitment Status : Unknown
Verified February 2016 by Fox Chase Cancer Center.
Recruitment status was:  Active, not recruiting
First Posted : November 6, 2007
Last Update Posted : February 5, 2016
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Fox Chase Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Unknown
Actual Primary Completion Date : October 2013
Estimated Study Completion Date : April 2017